Isotretinoin (Accutane): evidence, risks and regulation

Isotretinoin is a prescription capsule for severe, treatment-resistant nodular acne. It works, but it carries a boxed warning for birth defects, and in the US, UK and EU its use sits inside pregnancy-prevention programmes. The best evidence on depression and suicide finds no increase at population level, with real limits on that finding.

Key points

• The US label covers “severe recalcitrant nodular acne” in non-pregnant patients aged 12 and over who did not respond to conventional therapy, including oral antibiotics [1].
• The boxed warning is embryo-fetal toxicity. The US requires the iPLEDGE REMS; the EU and UK require pregnancy prevention programmes [1][2][4][6].
• A Cochrane review (31 trials, 3,836 people) rated most of the evidence low quality, and could not say whether isotretinoin cuts lesion counts more than antibiotics plus topical treatment [7].
• A 2023 meta-analysis of 25 observational studies (1.6 million people) found no population-level rise in suicide or psychiatric disorders [9]. Meta-analyses found no link to inflammatory bowel disease [10][11].
• Verdict on “delete acne (caution)” in A tier: partly supported. See below.

What isotretinoin is and where it is approved

Isotretinoin is an oral retinoid, a vitamin A derivative. Roaccutane and Accutane were the original brands; generics now dominate. This article is about the drug in general; it is not a research peptide and we do not compare prices for it.

United States (FDA). The generic label we read (Amneal Pharmaceuticals, DailyMed page showing “Updated November 4, 2026”, highlights revised 8/2026) lists one indication: severe recalcitrant nodular acne in non-pregnant patients 12 and over, with multiple inflammatory nodules of 5 mm or more, who are unresponsive to conventional therapy [1]. It is prescription-only and restricted by the iPLEDGE REMS [1].

United Kingdom (MHRA). Isotretinoin is a black triangle medicine, and in 2020 the MHRA said it should be prescribed only by a consultant dermatologist-led team [3]. Later notices changed who may initiate treatment (see “Who may prescribe”).

European Union (EMA). The 2018 retinoid review, concluded by a European Commission decision on 21 June 2018, required a pregnancy prevention programme for isotretinoin, acitretin and alitretinoin [6].

Germany (BfArM) and national EU registers: not checked.

The boxed warning and the pregnancy programmes

The US label’s boxed warning reads that isotretinoin “can cause life-threatening birth defects and is contraindicated in pregnancy.” If pregnancy occurs, treatment must stop and the patient be referred to an obstetrician-gynecologist experienced in reproductive toxicity [1].

iPLEDGE (US). The FDA says iPLEDGE was implemented in 2005 and approved as a REMS in 2010. It is a shared system covering all approved isotretinoin products [2]. Prescribers, pharmacies and distributors must be certified, and patients who can become pregnant must meet pregnancy-testing and contraception requirements [1][2]. The label asks for a pregnancy test before each prescription, at stopping and one month after, and says to avoid pregnancy from one month before treatment until one month after [1].

On 9 February 2026 the FDA approved modifications [2]. Prescribers may allow home pregnancy tests during and after treatment, with processes to reduce misreading and falsification; pre-treatment tests must still be done in a medical setting [2]. The FDA page says implementation was moved from 8 August 2026 to 15 November 2026 (page current as of 16 June 2026) [2]. The official iPLEDGE website loaded for us with only its title, so we rely on the FDA page and the label for the programme’s rules.

EU. The programme requires an assessment of each woman’s pregnancy potential, tests before, during and after treatment, at least one effective contraceptive method, and a risk acknowledgement form [6].

UK. All patients of childbearing potential must be enrolled in the Pregnancy Prevention Programme, must not become pregnant during treatment or for one month after, and have their enrolment recorded on an Acknowledgement of Risk Form [4].

Who may prescribe

In the US, only iPLEDGE-certified prescribers [1]. The label we read does not limit this to dermatologists.

In the UK the rules moved in three steps. In August 2020 the MHRA advised consultant dermatologist-led prescribing [3]. On 31 October 2023 it set out roles: a Lead Prescriber with expertise in systemic retinoids, a Follow-Up Prescriber, and for under-18s a second named professional who independently agreed isotretinoin was the most appropriate option [4]. On 22 January 2026 the MHRA dropped that second-prescriber requirement, citing access delays and little evidence of disagreement, and replaced it with clinical audits run by the British Association of Dermatologists and a revised risk form; other 2023 measures stay [5].

What the efficacy evidence shows

The approval rests on a long clinical history, but the formal trial base is thinner than most readers assume.

• Cochrane review (2018). 31 randomised trials, 3,836 participants aged 12 to 55 with mild to severe acne, mostly 8 to 32 weeks of treatment. Against oral antibiotics plus topical agents in moderate or severe acne, there was no clear difference in inflammatory lesion counts (very low-quality evidence). Isotretinoin may slightly improve physician-assessed severity and caused more minor adverse effects such as dry skin and lips (low-quality evidence). None of the included trials reported birth defects. The authors called for better trials and safety reporting [7]. We read the review record through Europe PMC, not the full text.
• Label trial. The label’s efficacy study randomised 925 people (397 aged 12 to 17) to two isotretinoin capsule products, not placebo. At week 20, 70% (324/464) and 75% (344/461) had at least a 90% reduction in nodular lesions [1]. It shows two products perform alike, not how isotretinoin compares with other treatments.
• Relapse. A single-centre prospective study of 180 people with treatment-resistant acne (116 completed 12 months) reported that 97.4% said their acne had improved at 12 months, with relapse in 32.7% and retreatment in 1.7%. Relapse was higher in the group with lower cumulative exposure (47.4% vs 26.9%). It is observational, and funding was not stated in the record we saw [8]. We did not find a pooled relapse rate we could open.

We did not open the 2024 American Academy of Dermatology acne guideline, and summaries we saw disagreed on how it grades isotretinoin, so we make no claim about it.

Risks and unknowns

Birth defects. The central risk, covered above. Blood donation is also restricted during and after treatment [1].

Psychiatric effects: the conflicting evidence. The US label lists depression, psychosis, suicidal ideation and aggressive or violent behaviour as reported events [1]. The MHRA states that depression, anxiety and psychotic symptoms have been reported, suicidal thoughts and suicide “very rarely”, and that symptoms may not fully resolve after stopping [3]. The EMA’s 2018 review could not clearly establish a causal link; its warning reflects that severe skin disease itself raises psychiatric risk [6].

The largest synthesis is a 2023 JAMA Dermatology meta-analysis of 25 observational studies, 1,625,891 participants (searches to January 2023). Pooled one-year absolute risks among users were 0.07% for completed suicide, 0.14% for attempts, 0.47% for ideation, 0.35% for self-harm and 3.83% for depression (11 studies). Against non-users, suicide attempt risk was lower 2 to 4 years after treatment (for example RR 0.86, 95% CI 0.77 to 0.95 at three years), not significant during treatment (RR 0.84, 95% CI 0.45 to 1.56), and all psychiatric disorders showed no significant association (RR 1.08, 95% CI 0.99 to 1.19). The authors listed heterogeneity, imprecision, confounding by indication and detection bias as limitations. The lead funder was a university grant; one author reported industry ties with several pharmaceutical companies [9].

Population-level null results cannot rule out harm in individuals, and the studies are observational. Both the label and regulators therefore keep monitoring advice [1][4][6].

Sexual dysfunction. The MHRA lists erectile dysfunction, reduced libido and vaginal dryness, incidence unknown and thought rare [3]; the 2023 update added sexual function assessment at follow-up [4].

Liver and lipids. The label warns of clinical hepatitis, with liver enzyme elevations in about 15% of trial participants, and of triglycerides above 800 mg/dL, with fasting lipid monitoring [1]. Pancreatitis, including rare fatal cases, is also listed [1]. The label says lipid problems usually resolve after treatment ends [1].

Inflammatory bowel disease. The label warns of IBD reports even in patients without prior bowel disease [1]. Epidemiology does not show a rise. A 2023 meta-analysis of 8 studies (2,522,422 people) found an odds ratio of 1.01 (95% CI 0.80 to 1.27) for IBD, 0.87 for Crohn disease and 1.27 (0.94 to 1.73) for ulcerative colitis [11]. A 2013 nested case-control study of 2,159 cases found an adjusted RR of 0.99 for IBD, though only 10 cases had used isotretinoin [10]. The ulcerative colitis upper bounds are wide enough that a modest effect is not excluded.

Other. Bone mineral density declines in 9% of paediatric trial subjects without recovery on repeat scans, hearing impairment, ocular effects, intracranial hypertension and serious skin reactions are in the label [1]. Dry lips and skin are the most common effects [1][7].

Not studied well. Long-term mental health in adolescents, rates of sexual dysfunction, and head-to-head trials against modern combination regimens.

The source post and a verdict

On 22 October 2026 @Hoostethics posted a tier-list image captioned “ranking looksmaxxing techniques” [12]. The post text was read through the fxtwitter mirror; we could not view the image itself. Our source file lists “delete acne (caution)” (Accutane/isotretinoin) in A tier. See the full tier-list check for the other entries.

Verdict: partly supported. The efficacy claim holds for the labelled group: severe nodular acne unresponsive to other treatment, where regulators have kept the drug for decades. The “caution” is warranted: boxed warning, a restricted-access programme, and monitoring for mood, liver and lipids. What does not hold is any reading of A tier as a general tool. The label is for severe recalcitrant nodular acne, not mild acne or cosmetic polish, and the trial evidence is thinner and lower in quality than the reputation suggests [1][7]. The depression fear is not borne out at population level [9], but that is not a guarantee for any one person.

Frequently asked questions

Is isotretinoin the same as Accutane? Accutane was a brand of isotretinoin; the US label we read is a generic and carries the same active ingredient. In the UK the brand name is Roaccutane [1][3].

Does isotretinoin cause depression or suicide? Labels and regulators list psychiatric events as reported, and the EMA could not confirm a causal link [1][6]. A 2023 meta-analysis of 25 studies found no population-level increase in suicide or psychiatric disorders, with caveats about bias and heterogeneity [9].

Does isotretinoin cause inflammatory bowel disease? The label warns of reports [1]. Two meta-analyses (5 and 8 studies) found no significant association with IBD overall [10][11].

Who can prescribe isotretinoin? In the US, iPLEDGE-certified prescribers [1]. In the UK, a Lead Prescriber with systemic retinoid expertise; since 22 January 2026 a second prescriber’s agreement is no longer required for under-18s [4][5].

Sources

1. Amneal Pharmaceuticals, “Isotretinoin capsules” prescribing information, DailyMed (page updated 4 Nov 2026; highlights revised 8/2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f1c8971-c6dc-4708-848b-5cee50b6c32a
2. US FDA, “iPLEDGE Risk Evaluation and Mitigation Strategy (REMS)” (page current as of 16 Jun 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems
3. MHRA, “Isotretinoin (Roaccutane): reminder of important risks and precautions” (26 Aug 2020, with later post-publication notes). https://www.gov.uk/drug-safety-update/isotretinoin-roaccutane-reminder-of-important-risks-and-precautions
4. MHRA, “Isotretinoin (Roaccutane): introduction of new safety measures including additional oversight of the initiation of treatment for patients under 18 years of age” (31 Oct 2023). https://www.gov.uk/drug-safety-update/isotretinoin-roaccutanev-introduction-of-new-safety-measures-including-additional-oversight-of-the-initiation-of-treatment-for-patients-under-18-years-of-age
5. MHRA, “Isotretinoin prescribing requirements updated with revised risk minimisation measures” (22 Jan 2026). https://www.gov.uk/government/news/isotretinoin-prescribing-requirements-updated-with-revised-risk-minimisation-measures
6. European Medicines Agency, “Retinoid-containing medicinal products: referral” (PRAC 8 Feb 2018, CHMP 22 Mar 2018, EC decision 21 Jun 2018). https://www.ema.europa.eu/en/medicines/human/referrals/retinoid-containing-medicinal-products
7. Cochrane Database Syst Rev, “Oral isotretinoin for acne” (Nov 2018), DOI 10.1002/14651858.CD009435.pub2; record read via Europe PMC, PMID 30484286. https://pubmed.ncbi.nlm.nih.gov/30484286/
8. Blasiak RC et al., “High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris”, JAMA Dermatology 149(12):1392-1398 (Dec 2013); abstract read via Europe PMC. https://pubmed.ncbi.nlm.nih.gov/24173086/
9. JAMA Dermatology, meta-analysis of isotretinoin and risk of suicide and psychiatric disorders (2023; searches to 24 Jan 2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10687715/
10. Etminan M et al., “Isotretinoin and risk for inflammatory bowel disease”, JAMA Dermatology 149(2) (2013). https://jamanetwork.com/journals/jamadermatology/fullarticle/1654866
11. Am J Clin Dermatol 24(5):721-730, systematic review and meta-analysis with trial sequential analysis of isotretinoin and IBD (online 3 Apr 2023); abstract read via Europe PMC, PMID 37010780. https://pubmed.ncbi.nlm.nih.gov/37010780/
12. @Hoostethics, “ranking looksmaxxing techniques” (22 Oct 2026), text read through the fxtwitter mirror. https://x.com/Hoostethics/status/2113302148750758106

This article is information, not medical advice.